Core Viewpoint - A class action lawsuit has been filed against Jayud Global Logistics Ltd. for allegedly making false and misleading statements regarding its business and operations during the class period from April 21, 2023, to April 30, 2025 [2][3]. Group 1: Allegations - The lawsuit claims that Jayud was involved in a fraudulent stock promotion scheme that included misinformation on social media and impersonation of financial professionals [3]. - It is alleged that insiders and affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [3]. - The complaint states that Jayud's public statements and risk disclosures did not mention the false rumors and artificial trading activity that influenced the stock price, rendering the company's positive statements materially misleading [3]. Group 2: Legal Process - Investors who purchased Jayud securities during the class period have until January 19, 2026, to apply to be appointed as lead plaintiff in the lawsuit [2]. - The law firm Bragar Eagel & Squire, P.C. is encouraging affected investors to contact them for more information regarding their legal rights and options [4]. Group 3: Firm Information - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation, including securities and commercial cases [5]. - The firm operates nationwide with offices in New York, South Carolina, and California, and handles cases in both federal and state courts [5].

Core Viewpoint - A class action lawsuit has been filed against Freeport-McMoRan Inc. for allegedly making false and misleading statements regarding safety at the Grasberg Block Cave mine in Indonesia, which may have led to investor losses [3][6]. Allegation Details - The lawsuit claims that Freeport did not adequately ensure safety at the Grasberg Block Cave mine, creating a heightened risk of worker fatalities [3]. - It is alleged that the lack of proper safety precautions constituted undisclosed regulatory, litigation, and reputational risks [3]. - The defendants' statements about Freeport-McMoRan's business and operations were materially false and misleading, lacking a reasonable basis [3]. Next Steps - Investors who purchased Freeport shares between February 15, 2022, and September 24, 2025, and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4][6]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is January 12, 2026 [6]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation, including securities and commercial litigation [5]. - The firm operates nationwide and handles cases in both federal and state courts [5].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited for allegedly making false and misleading statements regarding its prostate cancer therapeutic candidates and supply chain quality, leading to investor losses during the specified class period [3][7]. Allegation Details - The lawsuit claims that defendants materially overstated the progress of Telix's prostate cancer therapeutic candidates [3]. - It is alleged that the quality of Telix's supply chain and partners was also overstated [3]. - As a result, statements made by the defendants about Telix's business, operations, and prospects were materially false and misleading, lacking a reasonable basis [3]. Next Steps - Investors who purchased or acquired Telix shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is January 9, 2026 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across state and federal courts [5]. - The firm has offices in New York, California, and South Carolina [5].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for allegedly misleading investors regarding its operational practices and financial health during the class period from October 22, 2024, to October 28, 2025 [2][7]. Allegation Details - The lawsuit claims that Stride made false statements about being a leading technology-based education company, while in reality, it was inflating enrollment numbers by retaining "ghost students" and cutting staffing costs beyond legal limits [7]. - Additional allegations include ignoring compliance requirements, suppressing whistleblowers, and losing existing and potential enrollments, which led to investors purchasing securities at artificially inflated prices [7]. Next Steps - Investors who acquired Stride shares during the class period and suffered losses are encouraged to contact Bragar Eagel & Squire for more information and to discuss their legal rights [4].

Core Viewpoint - A class action lawsuit has been filed against Six Flags Entertainment Corporation regarding the merger with Cedar Fair, alleging that the registration statement failed to disclose significant underinvestment issues and operational challenges faced by Legacy Six Flags prior to the merger [2][7]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased or acquired Six Flags common stock related to the merger registration statement issued on July 1, 2024 [2]. - Investors have until January 5, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The registration statement allegedly did not reveal that Legacy Six Flags had chronic underinvestment and required millions in additional capital and operational expenditures to maintain its market share [7]. - Following the appointment of CEO Selim Bassoul in November 2021, significant employee layoffs were made to cut costs, which reportedly degraded operational competence and guest experience [7]. - On the merger closing date, Six Flags stock was trading above $55 per share, but subsequently fell to as low as $20 per share, marking a decline of nearly 64% [7]. Group 3: Next Steps for Investors - Investors who suffered losses or have information regarding the claims are encouraged to contact the law firm for further details and assistance [4].

Core Viewpoint - A class action lawsuit has been filed against Klarna Group plc for allegedly misleading investors regarding the company's financial health and risk disclosures related to its IPO on September 10, 2025 [8]. Allegation Details - The lawsuit claims that Klarna's Registration Statement contained false and misleading statements, particularly regarding the underestimation of loss reserves that would increase shortly after the IPO [8]. - It is alleged that the defendants either knew or should have known about the risk profile of individuals taking Klarna's buy now, pay later loans, which contributed to the misleading nature of their public statements [8]. Financial Impact - Klarna's IPO involved the sale of 34,311,274 shares at a price of $40.00 per share [8]. - Following the announcement of disappointing Q3 2025 financial results on November 18, 2025, which included a significant increase in credit loss provisions, Klarna's share price fell by $3.25, or approximately 9.3%, from $34.88 to $31.63 [8]. Next Steps - Investors who purchased Klarna shares and suffered losses are encouraged to contact Bragar Eagel & Squire, P.C. to discuss their legal rights and options [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is February 20, 2026 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation, including securities and commercial litigation [5].

Core Viewpoint - A class action lawsuit has been filed against Avantor, Inc. for alleged misrepresentations regarding its competitive position and financial performance during the specified class period from March 5, 2024, to October 28, 2025 [2][7]. Allegation Details - The lawsuit claims that Avantor's management failed to disclose that the company's competitive positioning was weaker than publicly represented, and that it was facing negative impacts from increased competition [7]. - The complaint highlights that the company's financial results for Q3 2025 were disappointing, reporting a -5% organic revenue growth and a net loss of $712 million, primarily due to a non-cash goodwill impairment charge of $785 million [7]. - The impairment charge was attributed to "competitive pressures" that significantly affected the company's margins, along with the loss of several large accounts [7]. Stock Performance Impact - Following the announcement of the weak financial results, Avantor's stock price fell by $3.50 per share, a decline of over 23%, from $15.08 on October 28, 2025, to $11.58 on October 29, 2025 [7].

Core Points - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered systemic defects leading to serious patient risks [3][7] - The lawsuit covers individuals who purchased Baxter common stock between February 23, 2022, and October 29, 2025, with a deadline of December 15, 2025, for investors to apply as lead plaintiffs [7] Allegation Details - The complaint claims that Baxter failed to disclose critical information about the Novum LVP, including systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, which posed risks of serious injury or death to patients [3] - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures, leading to continued harm [3] - The lawsuit suggests that Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were materially false and misleading [3] Next Steps - Investors who suffered losses and wish to learn more about the claims or have questions are encouraged to contact the law firm Bragar Eagel & Squire, P.C. for further information [4] - The firm emphasizes that there is no cost or obligation for investors to inquire about their rights [4] About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in complex litigation across state and federal courts [5]

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited for allegedly making false and misleading statements regarding its prostate cancer therapeutic candidates and supply chain quality, leading to investor losses during the specified Class Period [3][7]. Allegation Details - The lawsuit claims that defendants materially overstated the progress of Telix's prostate cancer therapeutic candidates [3]. - It is alleged that the quality of Telix's supply chain and partners was also overstated [3]. - As a result, statements made by the defendants about Telix's business, operations, and prospects were materially false and misleading, lacking a reasonable basis [3]. Next Steps - Investors who purchased or acquired Telix shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is January 9, 2026 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

Core Points - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding its drug candidate sonelokimab (SLK) [8] - The lawsuit claims that MoonLake promoted SLK as superior to competing drugs while failing to disclose its lack of proven superiority [8] - Following the announcement of disappointing Phase 3 trial results, MoonLake's stock price dropped nearly 90%, resulting in significant investor losses [8] Allegation Details - The lawsuit alleges that MoonLake and its executives misrepresented the clinical advantages of SLK, which was claimed to have a unique Nanobody structure [8] - It is claimed that SLK targeted the same molecules as UCB's BIMZELX, contradicting the company's assertions of superiority [8] - The stock price fell 89.9% on September 29, 2025, after the announcement of the Phase 3 trial results [8] Next Steps - Investors who purchased MoonLake shares between March 10, 2024, and September 29, 2025, are encouraged to contact the law firm for more information and to discuss their legal rights [4] - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is December 15, 2025 [8]